Total Payments
$3,637
2024 Payments
$1,373
Companies
30
Transactions
91
Medicare Patients
3,512
Medicare Billing
$463,868
Payment Breakdown by Category
Food & Beverage$2,200 (60.5%)
Travel$1,428 (39.3%)
Education$8.75 (0.2%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,200 | 87 | 60.5% |
| Travel and Lodging | $1,428 | 3 | 39.3% |
| Education | $8.75 | 1 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| NEUROPACE, INC. | $1,636 | 5 | $0 (2017) |
| Neurelis, Inc. | $219.59 | 9 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $171.77 | 12 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $154.31 | 3 | $0 (2024) |
| Janssen Biotech, Inc. | $147.18 | 11 | $0 (2024) |
| Neurocrine Biosciences, Inc. | $138.12 | 6 | $0 (2024) |
| UCB, Inc. | $132.46 | 2 | $0 (2017) |
| Amgen Inc. | $124.08 | 2 | $0 (2024) |
| ABBVIE INC. | $82.02 | 3 | $0 (2024) |
| Celgene Corporation | $79.32 | 4 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,373 | 70 | Neurelis, Inc. ($219.59) |
| 2023 | $150.14 | 7 | LivaNova USA, Inc. ($43.52) |
| 2021 | $106.94 | 1 | Amgen Inc. ($106.94) |
| 2019 | $193.73 | 5 | Novartis Pharmaceuticals Corporation ($125.71) |
| 2018 | $44.96 | 1 | Sunovion Pharmaceuticals Inc. ($44.96) |
| 2017 | $1,768 | 7 | NEUROPACE, INC. ($1,636) |
All Payment Transactions
91 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $29.81 | General |
| Category: Neuropsychiatry | ||||||
| 11/26/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $23.41 | General |
| Category: Neuroscience | ||||||
| 11/26/2024 | Boston Scientific Corporation | WATCHMAN FLX (Device) | Food and Beverage | In-kind items and services | $21.78 | General |
| Category: WATCHMAN FLX_IC | ||||||
| 11/25/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $14.64 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/22/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $17.14 | General |
| Category: Inflammation | ||||||
| 11/21/2024 | Ceribell, Inc. | POCKET EEG DEVICE (Device) | Food and Beverage | Cash or cash equivalent | $22.14 | General |
| Category: Neurology | ||||||
| 11/20/2024 | Neurelis, Inc. | VALTOCO (Drug) | Food and Beverage | In-kind items and services | $38.02 | General |
| Category: EPILEPSY | ||||||
| 11/20/2024 | Neurelis, Inc. | VALTOCO (Drug) | Food and Beverage | In-kind items and services | $5.74 | General |
| Category: EPILEPSY | ||||||
| 11/19/2024 | Teva Pharmaceuticals USA, Inc. | UZEDY (Drug) | Food and Beverage | In-kind items and services | $18.85 | General |
| Category: Neurology | ||||||
| 11/14/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $18.38 | General |
| Category: PSYCHIATRY | ||||||
| 11/12/2024 | Neurelis, Inc. | VALTOCO (Drug) | Food and Beverage | In-kind items and services | $28.96 | General |
| Category: EPILEPSY | ||||||
| 11/12/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $19.29 | General |
| Category: Central Nervous System | ||||||
| 11/04/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $2.97 | General |
| Category: Central Nervous System | ||||||
| 10/22/2024 | Genentech USA, Inc. | Ocrevus Zunovo (Biological) | Food and Beverage | In-kind items and services | $24.37 | General |
| Category: Immunology | ||||||
| 10/15/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $19.00 | General |
| Category: NEUROLOGY | ||||||
| 10/14/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $28.78 | General |
| Category: NEUROSCIENCE | ||||||
| 10/11/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $26.56 | General |
| Category: Neuropsychiatry | ||||||
| 10/01/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $19.68 | General |
| Category: Central Nervous System | ||||||
| 09/27/2024 | Travere Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $22.23 | General |
| 09/26/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $20.06 | General |
| Category: Immunology | ||||||
| 09/26/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $1.94 | General |
| Category: Immunology | ||||||
| 09/26/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $0.68 | General |
| Category: Immunology | ||||||
| 09/13/2024 | Neurelis, Inc. | VALTOCO (Drug) | Food and Beverage | In-kind items and services | $35.45 | General |
| Category: EPILEPSY | ||||||
| 09/03/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $24.96 | General |
| Category: Neuropsychiatry | ||||||
| 08/27/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $26.95 | General |
| Category: Cardiovascular | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 982 | 1,462 | $359,396 | $134,136 |
| 2022 | 7 | 844 | 1,364 | $314,378 | $117,804 |
| 2021 | 6 | 805 | 1,141 | $267,930 | $105,532 |
| 2020 | 6 | 881 | 1,138 | $266,346 | $106,398 |
Total Patients
3,512
Total Services
5,105
Medicare Billing
$463,868
Procedure Codes
30
All Medicare Procedures & Services
30 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99349 | Residence visit for established patient with moderate level of medical decision making, per day, if using time, at least 40 minutes | Office | 2023 | 467 | 864 | $226,316 | $86,469 | 38.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 83 | 106 | $36,040 | $12,925 | 35.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 61 | 61 | $27,267 | $9,360 | 34.3% |
| 99344 | Residence visit for new patient with moderate level of medical decision making, per day, if using time, at least 60 minutes | Office | 2023 | 50 | 50 | $18,825 | $5,857 | 31.1% |
| G0179 | Physician or allowed practitioner re-certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians a | Office | 2023 | 99 | 140 | $12,146 | $4,757 | 39.2% |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 2023 | 99 | 110 | $12,496 | $4,674 | 37.4% |
| 99497 | Advance care planning, first 30 minutes | Office | 2023 | 60 | 60 | $10,174 | $4,079 | 40.1% |
| 99350 | Residence visit for established patient with high level of medical decision making, per day, if using time, at least 60 minutes | Office | 2023 | 14 | 22 | $8,066 | $3,140 | 38.9% |
| 95819 | Measurement of brain wave activity (eeg), awake and asleep | Facility | 2023 | 25 | 25 | $3,075 | $1,127 | 36.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 11 | 11 | $2,750 | $914.10 | 33.2% |
| 99342 | Residence visit for new patient with low level of medical decision making, per day, if using time, at least 30 minutes | Office | 2023 | 13 | 13 | $2,241 | $832.72 | 37.2% |
| 99349 | Established patient home visit, typically 40 minutes | Office | 2022 | 529 | 975 | $255,392 | $96,276 | 37.7% |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 2022 | 99 | 116 | $13,178 | $5,039 | 38.2% |
| G0179 | Physician or allowed practitioner re-certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians a | Office | 2022 | 93 | 142 | $12,320 | $4,747 | 38.5% |
| 99497 | Advance care planning, first 30 minutes | Office | 2022 | 59 | 59 | $10,004 | $4,084 | 40.8% |
| 99343 | New patient home visit, typically 45 minutes | Office | 2022 | 36 | 36 | $10,129 | $3,476 | 34.3% |
| 99344 | New patient home visit, typically 1 hour | Office | 2022 | 16 | 16 | $6,024 | $2,413 | 40.1% |
| 99350 | Established patient home visit, typically 1 hour | Office | 2022 | 12 | 20 | $7,332 | $1,768 | 24.1% |
| 99349 | Established patient home visit, typically 40 minutes | Office | 2021 | 540 | 851 | $222,809 | $88,192 | 39.6% |
| 99343 | New patient home visit, typically 45 minutes | Office | 2021 | 49 | 49 | $13,787 | $4,678 | 33.9% |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 2021 | 93 | 100 | $11,360 | $4,446 | 39.1% |
| G0179 | Physician or allowed practitioner re-certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians a | Office | 2021 | 67 | 85 | $7,375 | $2,972 | 40.3% |
| 99497 | Advance care planning by the physician or other qualified health care professional, first 30 minutes | Office | 2021 | 41 | 41 | $6,952 | $2,936 | 42.2% |
| 99344 | New patient home visit, typically 60 minutes | Office | 2021 | 15 | 15 | $5,648 | $2,307 | 40.8% |
| 99349 | Established patient home visit, typically 40 minutes | Office | 2020 | 572 | 793 | $207,718 | $82,297 | 39.6% |
About Ahmad Daif
Ahmad Daif is a Clinical Neurophysiology healthcare provider based in Chicago, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/09/2014. The National Provider Identifier (NPI) number assigned to this provider is 1326459553.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Ahmad Daif has received a total of $3,637 in payments from pharmaceutical and medical device companies, with $1,373 received in 2024. These payments were reported across 91 transactions from 30 companies. The most common payment nature is "Food and Beverage" ($2,200).
As a Medicare-enrolled provider, Daif has provided services to 3,512 Medicare beneficiaries, totaling 5,105 services with total Medicare billing of $463,868. Data is available for 4 years (2020–2023), covering 30 distinct procedure/service records.
Ad
Practice Information
- Specialty Clinical Neurophysiology
- Other Specialties Neurology, General Practice
- Location Chicago, IL
- Active Since 05/09/2014
- Last Updated 01/23/2026
- Taxonomy Code 2084N0600X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1326459553
Products in Payments
- RNS System (Device) $1,636
- VALTOCO (Drug) $219.59
- Austedo XR (Drug) $146.49
- INGREZZA (Drug) $138.12
- Briviact (Drug) $132.46
- Aimovig (Biological) $106.94
- TREMFYA (Drug) $88.30
- ZEPOSIA (Drug) $79.32
- REXULTI (Drug) $74.82
- ENTYVIO (Biological) $73.63
- BOTOX (Biological) $68.13
- Leqembi (Drug) $65.30
- STELARA (Biological) $58.88
- VOQUEZNA (Drug) $57.02
- APTIOM (Drug) $44.96
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR (Device) $43.52
- VYEPTI (Biological) $41.50
- KESIMPTA (Drug) $28.60
- QULIPTA (Drug) $28.59
- HADLIMA (Drug) $27.95
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Clinical Neurophysiology Doctors in Chicago
Dr. Micheal Macken, Md, MD
Clinical Neurophysiology — Payments: $611,402
Clinical Neurophysiology $611,402
Dr. Sumayyah Abumurad, Md, MD
Clinical Neurophysiology — Payments: $85,391
Clinical Neurophysiology $85,391
Akash Patel, Do, DO
Clinical Neurophysiology — Payments: $6,674
Clinical Neurophysiology $6,674
Dr. Diana Mnatsakanova, M.d, M.D
Clinical Neurophysiology — Payments: $2,288
Clinical Neurophysiology $2,288
Dr. David Bieber
Clinical Neurophysiology — Payments: $970.59
Clinical Neurophysiology $970.59
Serge Pierre-Louis, M.d, M.D
Clinical Neurophysiology — Payments: $319.59
Clinical Neurophysiology $319.59